Zentiva announce that it have extended strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe. The products are indicated in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.26 RON | +0.62% | -0.61% | +11.64% |
1st Jan change | Capi. | |
---|---|---|
+11.64% | 488M | |
+21.20% | 43.18B | |
+20.67% | 22.59B | |
+16.19% | 14.56B | |
+41.76% | 11.5B | |
-8.37% | 6.93B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+10.21% | 5.36B | |
-2.27% | 4.81B |
- Stock Market
- Equities
- SCD Stock
- News Zentiva S.A.
- Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology